Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure

Abstract

In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013).

Targeting the sarcomere to correct muscle function

“…The results have not yet been published, but they were announced at the European Society for Cardiology Congress 2013 (REF. 86). The primary end point was an improvement in symptoms of dyspnoea.…”

In‐hospital worsening heart failure: a clinically relevant endpoint?

“…In line with these recommendations, several ongoing and recently completed AHF trials include in‐hospital WHF as a prospectively defined endpoint ( Table 2, 27, 28, 29, 30, 31, 32, 33, 34, 35); this is likely to contribute to its validation and increase physician familiarity with it as a clinical concept, as well as provide data on the effectiveness of interventions in preventing WHF.…”

Inotropes and vasopressors

“…Improvements in cardiac function were not associated with increased myocardial oxygen consumption when tested on dogs (36). In human studies omecamtivmecarbil showed dose-and concentration-dependent increases in systolic ejection time, stroke volume and ejection fraction (37,38). While the characteristic prolongation of systolic ejection time may be of concern, as long as relaxation is not prolonged and heart rate is not too high, this increased systolic ejection time should be well tolerated (4).…”